Market Overview

UPDATE: Oppenheimer Reiterates on Fluidigm on Revised View of Single-Cell Opportunity

Share:

In a report published Thursday, Oppenheimer analyst Matthew Pommer reiterated an Outperform rating on Fluidigm (NASDAQ: FLDM), and raised the price target from $28.00 to $35.00.

In the report, Oppenheimer noted, “We are increasing our price target and 2013-14 projections following discussions with Fluidigm and news that the UK's Medical Research Council (MRC) will offer new funding for single-cell research. It is our opinion that FLDM is positioned well for continued growth. We see the company's offerings for single-cell genomics as differentiated, and the early success of the C1 system as evidence of its utility to research laboratories. With an installed base of nearly 100 C1 systems ending 3Q13, we believe an installed base of ~400 units by year-end 2015 is achievable. We increase our target to $35 from $28 and reiterate our Outperform rating.”

Fluidigm closed on Wednesday at $32.03.

Latest Ratings for FLDM

DateFirmActionFromTo
Nov 2019Janney CapitalDowngradesBuyNeutral
Oct 2019UBSUpgradesNeutralBuy
Mar 2019UBSInitiates Coverage OnNeutral

View More Analyst Ratings for FLDM
View the Latest Analyst Ratings

 

Related Articles (FLDM)

View Comments and Join the Discussion!

Posted-In: Matthew Pommer OppenheimerAnalyst Color Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
ZTSMorgan StanleyMaintains125.0
VVVMorgan StanleyMaintains14.0
TEVAMorgan StanleyMaintains8.0
PFEMorgan StanleyMaintains36.0
PRGOMorgan StanleyMaintains53.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com